Monitoring of renal function among HIV-infected patients receiving tenofovir in a resource-limited setting

Journal of the International Association of Physicians in AIDS Care

Volumn 10, Issue 5, 2011, Pages 297-302

  Kiertiburanakul, Sasisopin ^a   Chaisiri, Kessarin ^b   Kasettratat, Narat ^c   Visuttimak, Pinyo ^b   Bowonwatanuwong, Chureeratana ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHONBURI HOSPITAL   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

creatinine clearance; glomerular filtration rate; HIV; renal function; tenofovir

Indexed keywords

CREATININE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; HIV INFECTIONS;

ADENINE; ANTI-HIV AGENTS; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; TENOFOVIR;

EID: 81755166026     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711406735     Document Type: Article

References (39)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS); 2011:1-166. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 21 January 2011.
2. Sungkanuparph S, Techasathit W, Utaipiboon C, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010 ; 4 (4). 515-528
3. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents, November 2009. Geneva: WHO; 2009. http://www.who.int/hiv/pub/arv/ rapid-advice-art.pdf. Accessed 20 January, 2011.
4. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 ; 304 (3). 321-333
5. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004 ; 292 (2). 191-201 (Pubitemid 38917996)
6. Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 2007 ; 17 (2). 90 99 C103-92 104
7. Cihlar T, Lin DC, Pritchard J, Fuller M, Mendel D, Sweet D. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates forhuman andrat renalorganicaniontransporter 1. Mol Pharmacol. 1999 ; 56 (3). 570-580 (Pubitemid 29406884)
8. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004 ; 43 (9). 595-612 (Pubitemid 38951802)
9. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res. 2010 ; 8 (7). 504-509
10. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002 ; 324 (6). 342-344 (Pubitemid 36109329)
11. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005 ; 40 (8). 1194-1198 (Pubitemid 40490248)
12. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004 ; 35 (3). 269-273 (Pubitemid 38280652)
13. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002 ; 40 (6). 1331-1333 (Pubitemid 35403147)
14. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS. 2010 ; 5 (6). 524-530
15. Gayet-Ageron A, Ananworanich J, Jupimai T, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother. 2007 ; 59 (5). 1034-1037 (Pubitemid 47073382)
16. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004 ; 37 (4). 1489-1495 (Pubitemid 39602339)
17. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009 ; 23 (15). 1971-1975
18. Gupta SK. Tenofovir and changes in renal function. Clin Infect Dis. 2005 ; 41 (4). 570 571-571
19. Madeddu G, Bonfanti P, De Socio GV, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008 ; 62 (1). 6-11
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16 (1). 31-41
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 ; 130 (6). 461-470 (Pubitemid 29135798)
22. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004 ; 8 (4). R204 - R212
23. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006 ; 7 (2). 105-111
24. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010 ; 51 (5). 496-505
25. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005 ; 6 (4). 284-290 (Pubitemid 41025294)
26. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. A thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008 ; 22 (16). 2155-2163
27. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008 ; 16 (4). 122-126
28. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003 ; 36 (8). 1070-1073 (Pubitemid 36513295)
29. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS. 2005 ; 19 (7). 421-424 (Pubitemid 41105521)
30. Ravasi G, Lauriola M, Tinelli C, Brandolini M, Uglietti A, Maserati R. Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients. HIV Med. 2009 ; 10 (4). 219-228
31. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008 ; 38 (1). 32-46 (Pubitemid 350256715)
32. Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant. 2005 ; 20 (9). 1791-1798 (Pubitemid 41222590)
33. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 ; 67 (6). 2089-2100 (Pubitemid 41623371)
34. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998 ; 32 (6). 992-999 (Pubitemid 28551162)
35. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985 ; 28 (5). 830-838 (Pubitemid 16156326)
36. Hansen AB, Mathiesen S, Gerstoft J. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J Infect Dis. 2004 ; 36 (5). 389-392 (Pubitemid 38967701)
37. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004 ; 18 (6). 960-963
38. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008 ; 197 (1). 102-108 (Pubitemid 351263473)
39. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009 ; 23 (6). 689-696